ArticleActa diabetologica2026
Polycythemia due to SGLT-2 inhibitors: who is at risk?
Article in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSodium-glucose co-transporter 2 (SGLT-2) inhibitors are oral antidiabetic agents that have been increasingly used in recent years. One of their lesser-known adverse effects is polycythemia (erythrocytosis), for which data remain limited. In this study, we aimed to investigate the incidence of erythrocytosis associated with SGLT-2 inhibitor use and the risk factors influencing these changes.
methodsAll patients who initiated SGLT-2 inhibitor therapy in our clinic between January 2020 and January 2021 were retrospectively evaluated. Hb and Hct levels were monitored for a median of 16 months following treatment initiation.
resultsPolycythemia developed in 15.1% (n = 58) of the 385 patients included in the study. Male sex and smoking were identified as significant risk factors for erythrocytosis, whereas insulin use and iron deficiency were found to be protective factors. The mean increase in hemoglobin levels among all patients was 0.97 ± 0.94 g/dL. A negative correlation was observed between baseline Hb levels and the degree of Hb increase associated with SGLT-2 inhibitor use. Patients who were excluded from the study due to baseline polycythemia (n = 18) were evaluated separately, and no significant change in their Hb levels was detected during follow-up.
conclusionsSGLT-2 inhibitors significantly increase Hb and Hct levels in all patients without polycythemia. In anemic individuals, SGLT-2 inhibitors appear to induce greater increases in Hb and Hct, suggesting a potential additional hematologic benefit in this subgroup. Moreover, SGLT-2 inhibitors have been shown to be safe in patients with pre-existing polycythemia.
Indexed as
Identifiers
42171708What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.